We are live on ! Find out more
AXDX

Accelerate Diagnostics
AXDX

Delisted

AXDX was delisted on the 14th of May, 2025.

Back to rankings

41 hedge funds and large institutions have $4.98M invested in Accelerate Diagnostics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $4.55M → $4.98M (+$426K)

11% less funds holding

Funds holding: 46 → 41 (-5)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
41
Holders Change
-5
Holders Change %
-10.87%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
9
Closed
7
Calls
$23K
Puts
–
Net Calls
+$23K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
CIA
Cladis Investment Advisory
Montana
+$41.5K
2
GAM
Griffin Asset Management
New York
+$27.6K
3
VF
Virtu Financial
New York
+$10.9K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.33K
5
IF
Ironwood Financial
Arizona
+$2.09K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$249K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$79.7K
3
OIM
Oracle Investment Management
Connecticut
-$41.7K
4
Northern Trust
Northern Trust
Illinois
-$29.3K
5
WAM
Warberg Asset Management
Illinois
-$19.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.88M -$249K -238,000 -13%
GAM
2
Griffin Asset Management
New York
$1.62M +$27.6K +26,400 +2%
BC
3
Birchview Capital
Vermont
$381K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$369K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$158K +$4.33K +4,144 +3%
CS
6
Cannell & Spears
New York
$134K -$174 -167 -0.1%
TWA
7
TCI Wealth Advisors
Arizona
$68.7K – – –
BlackRock
8
BlackRock
New York
$59.5K – – –
CIA
9
Cladis Investment Advisory
Montana
$46.4K +$41.5K +39,700 New
Northern Trust
10
Northern Trust
Illinois
$40.6K -$29.3K -28,034 -45%
BAM
11
Belpointe Asset Management
Nevada
$39.7K -$15 -14 -0%
IF
12
Ironwood Financial
Arizona
$25.5K +$2.09K +2,000 +10%
State Street
13
State Street
Massachusetts
$23.9K – – –
Millennium Management
14
Millennium Management
New York
$22.9K +$1.06K +1,019 +5%
Tudor Investment Corp
15
Tudor Investment Corp
Connecticut
$16.5K – – –
TC
16
Tejara Capital
United Kingdom
$15.9K – – –
Group One Trading
17
Group One Trading
Illinois
$15.7K -$164 -157 -1%
TIM
18
Thompson Investment Management
Wisconsin
$12.2K – – –
VF
19
Virtu Financial
New York
$12K +$10.9K +10,389 New
AF
20
Allworth Financial
California
$11.6K – – –
TRCT
21
Tower Research Capital (TRC)
New York
$8.61K -$938 -898 -11%
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$6K -$1.24K -1,191 -19%
CIBC Private Wealth Group
23
CIBC Private Wealth Group
Georgia
$4.61K – – –
Bank of America
24
Bank of America
North Carolina
$2.48K +$167 +160 +8%
Morgan Stanley
25
Morgan Stanley
New York
$1.59K +$1 +1 +0.1%
1
2

AXDX Hedge Fund Activity: Q2 2024 in Review

41 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2024, worth a combined $4.98M — up 9.4% from $4.55M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of AXDX and 2 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 8 added.

The largest buyer was Cladis Investment Advisory, opening a new position worth an estimated $41.5K. The largest seller was Armistice Capital, cutting an estimated $249K.

  • 41 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2024, down from 46 in Q1 2024.
  • Funds reported $4.98M of Accelerate Diagnostics stock for Q2 2024, up 9.4% quarter-over-quarter.
  • 2 funds opened new Accelerate Diagnostics positions in Q2 2024 and 7 closed out, a net change of -5 holders.
  • The largest Accelerate Diagnostics buyer in Q2 2024 was Cladis Investment Advisory, an estimated $41.5K added.
  • The largest Accelerate Diagnostics seller in Q2 2024 was Armistice Capital, an estimated $249K sold.

Based on aggregated 13F filings for Q2 2024.